(Q33604216)

28 July 2017

1 reference

title

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications (English)

1 reference

28 July 2017

Kaul DR

1

1 reference

28 July 2017

Cinti SK

series ordinal

2

1 reference

28 July 2017

Carver PL

series ordinal

3

1 reference

28 July 2017

Kazanjian PH

series ordinal

4

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

19

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

281-298

1 reference

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

"Buffalo hump" in men with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Indinavir-associated lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

21 January 2018

Indinavir nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Protease inhibitors and unusual bleeding in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Multiple cytokines stimulate hepatic lipid synthesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Insulin resistance and body fat distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Clinical pharmacokinetics of rifabutin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Protease inhibitor-associated hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Visceral abdominal-fat accumulation associated with use of indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

Severe premature coronary artery disease with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

High triglyceride levels as a predictor of mortality in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.4.281.30937

10.1592/PHCO.19.4.281.30937

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference